Liquidia posts Q2 2026 net income of $74.7M; YUTREPIA sales surge to $170.4M

Liquidia Corp

2026-Q2 EPS reported $1.26 revenue$304,544,000

YUTREPIA net sales $170.4M in Q2 2026, up 31% from Q1 2026; Q2 2025 product sales were $6.5M.
Net income $74.7M ($0.84 basic / $0.74 diluted EPS) vs. net loss of $41.6M in Q2 2025.
Adjusted EBITDA $96.3M; cash and equivalents $284.2M at June 30, 2026, up from $190.7M at year-end 2025.
~5,900 unique patient prescriptions and >5,000 patients started on YUTREPIA since June 2025 launch; >1,100 prescribers.
Enrollment underway in Re-Spire, pivotal study for L606; 10 clinical studies progressing across known and new indications.

Featured in Daily 8-K Digest

Selected #7 for 2026-08-12. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.